Related Experiment Video
Updated: Oct 10, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Effect of miRNA-200a on radiosensitivity of osteosarcoma cells by targeting Bone morphogenetic protein receptor 2
Xian Tao1, Jiansheng Cheng, Xinghua Wang1
1Department of Orthopedics, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, Jiangsu, China.
Abstract:
To study the effect of miR-200a on radiosensitivity of osteosarcoma cells and its mechanism. NC (normal cell) group, mimic-NC group, mimic-miR-200a group, inhibitor-NC group, inhibitor-miR-200a group, si-NC group, si-BMPR2 (Bone morphogenetic protein receptor 2) group, mimic-miR-200a+vector-NC group, and mimic-miR-200a+vector-BMPR2 group were set; the cells of the above groups were irradiated with different radiation intensities (0, 1, 2, 3, and 4 Gy). The expression of miR-200a and BMPR2 mRNA was detected by qRT-PCR; the expression of BMPR2 protein was detected by Western blot; cell viability was detected by MMT (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide); apoptosis rate was detected by flow cytometry. Cell clone formation experiment was used to detect cell radiosensitivity. Dual-luciferase reporter gene test was used to detect cell fluorescence activity. The expression of BMPR2 was high and the expression of miR-200a was low in osteosarcoma tissues after radiotherapy and in osteosarcoma cells after irradiation. Overexpression of miR-200a and interference with BMPR2 expression inhibits osteosarcoma cell proliferation, promotes apoptosis, and increases cellular radiosensitivity, miR-200a targets expression of BMPR2, and overexpression of BMPR2 reverses the radiosensitizing and apoptotic effects of miR-200a expression on osteosarcoma cells. Overexpression of miR-200a inhibits osteosarcoma cell proliferation, promotes apoptosis, and increases cellular radiosensitivity. The mechanism may be related to the regulation of BMPR2, which may provide new targets and new ideas for osteosarcoma treatment.
Insights
MicroRNA-200a (miR-200a) enhances osteosarcoma radiosensitivity by targeting Bone Morphogenetic Protein Receptor 2 (BMPR2). Upregulating miR-200a inhibits tumor growth and promotes apoptosis, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Osteosarcoma is a primary bone malignancy with limited treatment options.
- Radiotherapy is a key modality, but resistance remains a challenge.
- MicroRNAs (miRNAs) play crucial roles in cancer progression and treatment response.
Purpose of the Study:
- To investigate the role of miR-200a in osteosarcoma radiosensitivity.
- To elucidate the underlying molecular mechanism involving Bone Morphogenetic Protein Receptor 2 (BMPR2).
Main Methods:
- Quantitative real-time PCR (qRT-PCR) and Western blot for gene and protein expression analysis.
- Cell viability assays (MTT), apoptosis assays (flow cytometry), and colony formation assays.
- Dual-luciferase reporter assays to confirm direct targeting of BMPR2 by miR-200a.
Main Results:
- miR-200a expression was downregulated, while BMPR2 was upregulated in osteosarcoma tissues and cells post-radiotherapy.
- Overexpression of miR-200a or inhibition of BMPR2 suppressed cell proliferation, induced apoptosis, and increased radiosensitivity.
- miR-200a directly targets and downregulates BMPR2 expression.
- BMPR2 overexpression counteracted the radiosensitizing and pro-apoptotic effects of miR-200a.
Conclusions:
- miR-200a enhances osteosarcoma radiosensitivity by targeting BMPR2.
- This miR-200a/BMPR2 axis represents a potential therapeutic target for improving osteosarcoma treatment outcomes.
